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ABSTRACT 
Objective: Iron status is a modifiable trait that has been implicated in cardiovascular disease. 
This study uses the Mendelian randomization (MR) technique to investigate whether there is 
any causal effect of iron status on risk of coronary artery disease (CAD). 
Approach and Results: A two-sample MR approach is used to estimate the effect of iron 
status on CAD risk. Three loci (rs1800562 and rs1799945 in the HFE gene, and rs855791 in 
TMPRSS6) that are each associated with serum iron, transferrin saturation, ferritin and 
transferrin in a pattern suggestive of an association with systemic iron status are used as 
instruments. SNP-iron status association estimates are based on a GWAS meta-analysis of 
48,972 individuals. SNP-CAD estimates are derived by combining the results of a GWAS 
meta-analysis of 60,801 CAD cases and 123,504 controls with those of a meta-analysis of 
63,746 CAD cases and 130,681 controls obtained from Metabochip and GWAS studies. 
Combined MR estimates are obtained for each marker by pooling results across the three 
instruments. We find evidence of a protective effect of higher iron status on CAD risk (iron 
OR 0.94 per SD unit increase, 95%CI 0.88 to 1.00, p=0.039; transferrin saturation OR 0.95 
per SD unit increase, 95%CI 0.91 to 0.99, p=0.027; log-transformed ferritin OR 0.85 per SD 
unit increase, 95%CI 0.73 to 0.98, p=0.024; transferrin OR 1.08 per SD unit increase, 95%CI 
1.01 to 1.16, p=0.034). 
Conclusion: This MR study supports the hypothesis that higher iron status reduces CAD risk. 
These findings may highlight a therapeutic target.  
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ABBREVIATIONS 
CAD: coronary artery disease 
CHD: coronary heart disease 
CI: confidence interval 
GWAS: genome-wide association study 
IVW: inverse-variance weighted 
MR: Mendelian randomization 
RBC: red blood cell 
SNP: single-nucleotide polymorphism 
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INTRODUCTION 
Iron serves in a number of fundamental processes including erythropoiesis and cellular 
metabolism (1). Although iron status has been implicated in cardiovascular disease (1), the 
evidence for this is mixed. In support of a detrimental effect of higher iron status on 
cardiovascular risk, a reduced incidence of heart disease in premenopausal women as 
compared to men and postmenopausal women has been attributed to lower levels of stored 
iron (2). Higher iron stores have also been positively associated with risk factors for 
cardiovascular disease such as type 2 diabetes (3). Furthermore, genetic mutations resulting 
in hereditary haemochromatosis are associated with an increased incidence of 
cardiovascular morbidity (4), and chelation of heavy metals using disodium EDTA in patients 
that have experienced a recent myocardial infarction reduced adverse cardiovascular 
outcomes (5). However, these findings contrast with the results of a meta-analysis of 
observational studies that suggests a protective effect of higher iron status on the risk of 
coronary heart disease (CHD) (6). In addition, iron deficiency has been associated with 
increased mortality in patients with heart failure (7). 
It can be difficult to disentangle causal effects from spurious associations attributable to 
confounding and reverse causation in observational study. The Mendelian randomization 
(MR) approach can overcome these issues by using genetic variants such as single 
nucleotide polymorphisms (SNPs) as proxies or instruments for a phenotype or exposure of 
interest (8). It is because genetic variants are allocated randomly at the time of conception 
that this approach is not typically confounded by environmental, lifestyle factors or reverse 
causation. If the underlying assumptions of MR analysis are met (8), SNPs associated with 
iron status can be used as instruments in an investigation of the causal effect of iron status 
on risk of coronary artery disease (CAD). This principle has previously been adopted to 
explore the causal effect of iron status on atherosclerosis (9), and a similar approach has 
also been taken to show that red blood cell (RBC) traits are associated with risk of CHD (10). 
The instruments used in an MR study must influence the intermediate phenotype of interest 
(8, 11), which in this case is systemic iron status. Various correlated markers of iron status 
are available, including serum iron, transferrin saturation, ferritin and transferrin (1, 12-15). 
Genetic instruments for iron status that are used in an MR study should have a concordant 
association with each of these markers, and specifically SNPs that are deemed to increase 
systemic iron status should be associated with increased levels of serum iron, transferrin 
saturation and ferritin, and decreased levels of transferrin (9, 11, 16). Another potential 
limitation of the MR approach concerns pleiotropy, where genetic variants affect the outcome 
(CAD risk) through pathways that are independent of the intermediate phenotype of interest 
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(iron status), thus violating a fundamental assumption of MR to bias the causal effect 
estimates generated (8, 17). In this study, we select instruments for systemic iron status and 
perform an MR study investigating its causal effect on CAD risk. Furthermore, we explore 
the possibility that any pleiotropic effects of the instruments may be biasing the estimates 
generated.   
MATERIALS AND METHODS 
Materials and Methods are available in the online-only Data Supplement. The overall study 
design is demonstrated graphically in Figure 1. 
RESULTS 
The three instruments have F statistics for the four iron status markers ranging from 47 to 
2,127 (Table 1). Individual SNP-iron marker estimates are given in Table 1, while Table 2 
reports the SNP-CAD estimates from the meta-analysis of CARDIoGRAMplusC4D 1000G 
and CARDIoGRAMplusC4D Metabochip. 
Individual and pooled MR estimates for the effect of the four markers of iron status on risk of 
CAD are reported in Figure 2. The results, expressed as odds ratios (OR) for CAD per 
standard deviation unit increase in the iron status marker, demonstrate a protective effect on 
CAD risk for iron (OR 0.94, 95%CI 0.88 to 1.00, p=0.039), transferrin saturation (OR 0.95, 
95%CI 0.91 to 0.99, p=0.027) and (log-transformed) ferritin (OR 0.85, 95%CI 0.73 to 0.98, 
p=0.024). The effect estimate for transferrin (OR 1.08, 95%CI 1.01 to 1.16, p=0.034) is also 
in keeping with the other results to suggest that higher iron status is protective of CAD, as 
higher transferrin levels reflect lower iron status.  
Search of an online database of SNP-phenotype associations demonstrated that all three 
instruments are also associated with RBC traits (18, 19). Furthermore, the iron status raising 
allele at rs1800562 in the HFE gene is associated with lower low density lipoprotein levels 
and the iron status raising allele at rs1799945 in the HFE gene is associated with higher 
systolic and diastolic blood pressures (20, 21). 
DISCUSSION 
This work suggests a protective effect of higher iron status on the risk of CAD. The pooled 
MR estimates for serum iron, transferrin saturation, ferritin and transferrin all suggest that 
higher iron status lowers the risk of CAD. The objective of this study is to explore whether 
CAD risk is affected by iron status and instruments were selected to reflect this. The finding 
that all the considered iron status makers give similar causal estimates is consistent with the 
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effect of CAD risk being mediated by iron status rather than any individual marker. The small 
differences in estimates and confidence interval widths for the causal effects of the four 
markers might be explained by chance and possibly differential measurement error across 
markers, rather than indicating distinct causal pathways. In addition, the variation in 
magnitude of the MR estimate confidence intervals across the three SNPs for each iron 
status marker might also reflect the strengths of the SNP-iron status marker associations (as 
evaluated by the F statistics given in Table 1). In our current MR study, we demonstrate a 
causal effect of iron status on CAD risk using only the three SNPs associated with all four 
iron status markers at genome-wide significance. Given our interest in systemic iron status, 
we only include genetic variants that have shown genome-wide significant association with 
all four iron status markers in a pattern concordant with an effect on systemic iron status (i.e. 
increased levels of serum iron, transferrin saturation and ferritin, and decreased levels of 
transferrin) to minimise risk of including invalid instruments. For example, rs8177240 in the 
TF gene has genome-wide significant associations with serum iron and transferrin 
saturation, but in opposite directions (Supplementary Table I). As any effect on systemic iron 
status should have a concordant direction of effect on both serum iron and transferrin 
saturation, this genetic variant is unlikely to be a valid instrument. While our approach has 
the advantage of minimising risk of incorporating invalid instruments, it pays the price of 
sacrificing the additional power that might be afforded by considering as instruments all 
genetic variants associated with any iron status marker at genome-wide significance (22). 
A potential source of bias with the MR approach relates to the issue of pleiotropy (8, 17). 
While the availability of many instruments allows for implementation of statistical methods to 
detect and adjust for pleiotropy in sensitivity analyses, such techniques are not applicable 
when few instruments are available, such as in our study (23-27). Despite this, we have 
investigated the possibility of pleiotropy by searching for secondary phenotypes which have 
shown association with the three instruments. The association of the three iron status 
instruments with RBC traits may be expected given the well-established relationship 
between iron status and anaemia (12), but this would not bias the MR analysis if any effect 
of RBC traits on CAD risk was acting downstream of iron status, rather than independently of 
it (8, 17). The association of the iron status raising allele at rs1800562 (HFE gene) with lower 
low density lipoprotein (LDL) levels and the iron status raising allele at rs1799945 (HFE 
gene) with higher systolic and diastolic blood pressures are likely to be affecting CAD risk 
independently of iron status, and would therefore be expected to bias the MR estimates (20, 
21). Lower LDL levels and higher blood pressure are known to reduce and increase CAD 
risk respectively (20, 21). Consistent with the hypothesis of some bias attributable to 
pleiotropy, rs1800562 and rs1799945 give MR estimates for all markers that tend to 
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respectively over-estimate and under-estimate the effect of iron status on CAD risk as 
compared to rs855791 (TMPRSS6 gene), although the confidence intervals for the three 
SNPs largely overlap for all markers (Figure 2). Moreover, the pooled MR estimate across 
the three SNPs is comparable to that of rs855791 alone, which has no known pleiotropic 
associations. Thus, the overall conclusions of this work are unlikely to be severely affected 
by these pleiotropic effects. 
Early work attributed the observed association of heart disease with disorders of iron 
storage, older age in men and post-menopausal status in women to the effect of higher 
systemic iron status (2). However, consequent observational studies did not support this 
(28). A randomised controlled trial has demonstrated a protective effect of heavy metal 
chelation induced by disodium EDTA on heart disease, but it is unclear how generalizable 
this finding is, and the observed effect might be specific to patients that have suffered a 
recent myocardial infarction or attributable to effects independent of systemic iron status and 
overall body iron stores (5). By contrast, the conclusions of our MR study are in-keeping with 
a systematic review and meta-analysis of prospective observational studies investigating the 
association of body iron status and CHD risk (6). All except one of the 17 studies included in 
this meta-analysis adjusted for smoking and major cardiovascular risk factors such as blood 
pressure and lipid profile, with some studies also adjusting for social class and chronic 
disease (6). The risk ratio of CHD for individuals with levels of the iron status marker in the 
top third compared with individuals in the bottom third was 0.80 (95%CI 0.73 to 0.87) for 
iron, 0.82 (95%CI 0.75 to 0.89) for transferrin saturation, 1.03 (95%CI 0.87 to 1.23) for 
ferritin, and 0.99 (95%CI 0.86 to 1.13) for transferrin (6). The non-significant results for 
ferritin and transferrin might be attributable to confounding caused by inflammation, which 
would act to increase serum levels of ferritin and decrease those of transferrin (29), while 
increasing the risk of CHD (30), thus potentially biasing the ferritin-CHD and transferrin-CHD 
associations to mask a true protective effect of higher iron status on CHD. The authors 
concluded that while their overall results may suggest a protective effect of higher body iron 
stores on risk CHD, it is difficult to infer causality due to the possibility of residual 
confounding and reverse causality bias (6). For example, increased iron status has also 
been associated with risk of diabetes mellitus, which is an established risk factor for 
cardiovascular disease (3, 31). In our MR study, we have used genetic variants as 
instrumental variables for iron status to overcome these limitations of observational research 
and strengthen the evidence for a protective effect of iron status on CAD risk. 
Iron deficiency is a treatable condition that affects up to 2 billion people worldwide (1). The 
suggestion here that low iron status may have a causal effect on cardiovascular disease 
therefore has potentially significant clinical and public health implications. However, it is 
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important to interpret the findings of our MR study in context. While it is unlikely that 
pleiotropy is wholly responsible for the pattern of our results, we cannot completely exclude 
this. Compensatory developmental processes, referred to as canalization, can buffer the 
effects of genetic variation and may have impacted on our MR estimates, although this 
would be expected to bias results towards the null (32), We note that the Wald-type 
estimator has been shown to induce bias in the MR analysis of binary outcomes, although of 
small magnitude (e.g. < 10%) in typical MR analyses (33). Use of the same combined 
discovery and replication results from the GWAS meta-analysis to both identify the 
instruments and estimate their associations with iron status markers may also result in over-
estimation of the SNP-iron status associations (the Beavis effect or Winner’s Curse) (11, 34, 
35), in turn leading to underestimation of the true causal effect of iron status on CAD risk 
(bias towards the null), which in our two-sample MR analysis is estimated as the SNP-CAD 
association divided by the SNP-iron status association. Our use of instruments that have 
strong associations with all four markers of iron status should however minimise any effect of 
such bias (36). Finally, the conclusions of our work relate to patterns of iron status observed 
in the population-based studies contributing to the GIS consortium and therefore reflect 
effects in the general population. Further research is needed to investigate the causal effects 
of iron status on CAD risk in subjects with severe iron overload or deficiency. Similarly, our 
study does not offer insight into whether the estimates are equally applicable to both men 
and women. Despite these limitations, the results of this work show consistent and 
biologically plausible effects. Iron status may be affecting CAD risk via effects on RBCs (10, 
12). Iron deficiency is also known to impact cellular metabolism (37), and may increase CAD 
risk by this mechanism.  
In conclusion, this work is suggestive of a protective effect of higher iron status on risk of 
cardiovascular disease. This warrants further investigation, as these findings may highlight 
possible therapeutic targets and risk reduction strategies. 
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HIGHLIGHTS 
 Systemic iron status is a modifiable trait that has been implicated in cardiovascular 
disease. 
 Serum iron, transferrin saturation, ferritin and transferrin are all markers of systemic 
iron status. 
 By using genetic variants associated with these four markers as surrogates for 
systemic iron status, this study implements the Mendelian randomization approach to 
demonstrate a causal effect of systemic iron status on risk of coronary artery 
disease. 
 These findings may highlight a possible therapeutic target for the prevention and 
treatment of coronary artery disease.
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TABLES AND FIGURES 
 
Table 1. Results for the SNP-iron status associations (12). EA: effect allele; EAF: effect 
allele frequency, as reported by the Genetics of Iron Status consortium (12); R2:  percentage 
of the iron marker variation explained by the SNP (38); F: F statistic (39); GX: the per-allele 
effect on standard deviation units of the iron marker; GX SE: standard error of GX. 
 
Table 2. SNP-CAD associations obtained by meta-analysis of CARDIoGRAMplusC4D 
1000G (60,801 CAD cases and 123,504 controls) and CARDIoGRAMplusC4D Metabochip 
(63,746 CAD cases and 130,681 controls) using a summary data method that accounts for 
participant overlap between the two studies (34,997 cases and 49,512 controls) (40-42). EA: 
effect allele; GY: the per-allele effect on CAD, log(OR); GY SE: standard error of GY; p: p 
value. 
 
Figure 1. Graphical representation of the two-sample MR study design. Three SNPs that 
each have genome-wide significant associations with increased serum iron, transferrin 
saturation and ferritin, as well as decreased transferrin levels are used as instruments for 
systemic iron status. By using genetic variants associated with the four iron status markers 
as surrogates, the Mendelian randomization (MR) approach is used to estimate the causal 
effect of systemic iron status on risk of coronary artery disease (CAD). 
Figure 2. Forest plot of the SNP-specific and pooled MR estimates for the causal effect of 
each iron status marker on CAD risk (odds ratio, OR). The size of the black squares reflects 
the precision of the MR estimates and the horizontal lines indicate their 95% confidence 
intervals (95% CI). The pooled MR estimate is depicted by the centre of the diamond, with 
the corner edges on either side indicating the 95% CI. 
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Table 1 
  
 
SNP-iron status associations (n=48,972) 
  Iron (μmol/l) Transferrin saturation (%) Log10 Ferritin (μg/l) Transferrin (g/l) 
SNP EA EAF R2 F GX 
GX 
SE 
R2 F GX 
GX 
SE 
R2 F GX 
GX 
SE 
R2 F GX GX SE 
rs1800562 A 0.07 1.3 668 0.328 0.016 4.2 2127 0.577 0.016 0.5 256 0.204 0.016 2.9 1446 -0.479 0.016 
rs1799945 G 0.15 0.9 450 0.189 0.010 1.4 676 0.231 0.010 0.1 53 0.065 0.010 0.3 163 -0.114 0.010 
rs855791 G 0.55 1.6 806 0.181 0.007 1.8 889 0.190 0.008 0.1 73 0.055 0.007 0.1 47 -0.044 0.007 
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Table 2 
SNP EA GY GY SE p 
rs1800562 A -0.041 0.019 0.031 
rs1799945 G 0.006 0.012 0.585 
rs855791 G -0.014 0.008 0.097 
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Figure 1 
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Figure 2 
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Supplementary file 
MATERIALS AND METHODS 
 
GENETIC ASSOCIATIONS 
As markers of iron status, we consider serum iron (μmol/l), transferrin saturation (%), log10- 
transformed ferritin (μg/l) and transferrin (g/l) (1). The SNP-iron status association estimates 
are obtained from combined discovery and replication cohorts in a published genome-wide 
association study (GWAS) meta-analysis of 48,972 subjects of European descent performed 
by the Genetics of Iron Status (GIS) consortium, where adjustments were made for age, 
population stratification (ancestry principal components) and other study specific covariates 
(1). 
For the SNP-CAD association estimates, we use publicly available results from the 
CARDIoGRAMplusC4D 1000 Genomes-based GWAS (referred to here as 
CARDIoGRAMplusC4D 1000G) and CARDIoGRAMplusC4D Metabochip (2, 3). 
CARDIoGRAMplusC4D 1000G is a GWAS meta-analysis of 60,801 CAD cases and 123,504 
controls that adjusts for population stratification (genomic control method) (2). Participants 
are of European, east Asian, south Asian, Hispanic and African American ancestry (2). The 
diagnosis of CAD varies between studies; cases included subjects with documented acute 
coronary syndrome, coronary artery bypass grafting, percutaneous coronary 
revascularization, stenosis of greater than 50% in one or more of the coronary vessels, and 
cardiac angina (2). CARDIoGRAMplusC4D Metabochip is a meta-analysis of 63,746 CAD 
cases and 130,681 controls genotyped with either the Metabochip array or GWAS data 
imputed using HapMap (3). Participants are of European and south Asian descent (3). The 
study uses CAD definitions similar to CARDIoGRAMplusC4D 1000G and corrects for 
population stratification, age and sex (3). Results for both CARDIoGRAMplusC4D 1000G 
and CARDIoGRAMplusC4D Metabochip can be downloaded from 
www.CARDIoGRAMplusC4D.org (2, 3). We obtain SNP-CAD association estimates by 
meta-analysis of results from CARDIoGRAMplusC4D 1000G and CARDIoGRAMplusC4D 
Metabochip using a summary data method that accounts for participant overlap between the 
two studies (34,997 cases and 49,512 controls) (4). The approach ‘decouples’ the results 
from the two studies by transforming the covariance structure of the data such that  
metaanalysis methods assuming independence may consequently be applied (4). 
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INSTRUMENT SELECTION 
Increased systemic iron status is associated with increased levels of serum iron, transferrin 
saturation and ferritin, and decreased levels of transferrin (1, 5-8). Thus, these four 
correlated markers may be treated as surrogates of systemic iron status, the single 
intermediate phenotype of interest in our MR study. Genetic instruments for iron status 
should therefore be expected to have a concordant association with each of these four 
markers, and specifically SNPs that are deemed to increase systemic iron status should be 
associated with increased levels of serum iron, transferrin saturation and ferritin, and 
decreased levels of transferrin (9-11). The meta-analysis performed by the GIS consortium 
identified 12 genetic loci that differentially affect the four considered iron status markers 
(Supplementary Table 1) (1). Three loci (rs1800562 and rs1799945 in the HFE gene, and 
rs855791 in TMPRSS6) are associated with all four iron status markers at genome-wide 
significance (p < 5 x 10-8) in a pattern consistent with an effect on systemic iron status (i.e. 
increased levels of serum iron, transferrin saturation and ferritin, and decreased levels of 
transferrin) (Supplementary Table 1) (1, 11), and only these are considered as instruments 
for systemic iron status in our MR analysis. The rs1800562 and rs1799945 SNPs in the HFE 
gene are not in linkage disequilibrium (LD r2 < 0.01). 
The strength of each instrument is evaluated using its F statistic, and only SNPs with an F 
statistic greater than 10 are used, thus minimising any weak instrument bias (12, 13). 
 
MENDELIAN RANDOMIZATION ESTIMATES 
To derive MR estimates, a two-sample summary data approach is performed separately for 
each SNP using the Wald-type estimator, with standard error derived using the Delta method 
(14). Combined MR estimates are obtained by pooling MR estimates across SNPs using a 
fixed-effect inverse-variance weighted (IVW) meta-analysis. 
The overall study design is demonstrated graphically in Figure 1. 
 
PLEIOTROPY 
To explore the possibility that the instruments for iron status may be exerting effects on CAD 
risk through pleiotropic pathways that are independent of iron status and thus biasing the 
results of the MR analysis (15, 16), an online database of SNP-phenotype associations 
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(PhenoScanner, http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner) is used to 
search for secondary phenotypes associated with the three selected instruments at 
genomewide significance (p < 5 x 10-8) (17). 
All analyses are performed using the statistical programme R (version 3.3.1). 
 
REFERENCES 
1. Benyamin B, Esko T, Ried JS, et al. Novel loci affecting iron homeostasis and their 
effects in individuals at risk for hemochromatosis. Nat Commun. 2014;5:4926. 
2. Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genomewide 
association meta-analysis of coronary artery disease. Nat Genet. 2015;47:1121-1130. 
3. CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, et al. Large-scale 
association analysis identifies new risk loci for coronary artery disease. Nat Genet. 
2013;45:25-33. 
4. Han B, Duong D, Sul JH, de Bakker PI, Eskin E, Raychaudhuri S. A general 
framework for meta-analyzing dependent studies with overlapping subjects in association 
mapping. Hum Mol Genet. 2016;25:1857-1866. 
5. McLaren CE, Li KT, Gordeuk VR, Hasselblad V, McLaren GD. Relationship between 
transferrin saturation and iron stores in the African American and US Caucasian populations: 
analysis of data from the third National Health and Nutrition Examination Survey. Blood. 
2001;98:2345-2351. 
6. Beutler E, Felitti V, Ho NJ, Gelbart T. Relationship of body iron stores to levels of 
serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in 
patients with iron storage disease. Acta Haematol. 2002;107:145-149. 
7. Wangruangsathit S, Hathirat P, Chuansumrit A, Pakakasama S, Hongeng S. The 
correlation of transferrin saturation and ferritin in non-splenectomized thalassemic children. J 
Med Assoc Thai. 1999;82:S74-S6. 
8. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron 
deficiency and cardiovascular disease. Nat Rev Cardiol. 2015;12:659-669. 
9. Taylor AE, Davies NM, Ware JJ, VanderWeele T, Smith GD, Munafo MR. Mendelian 
randomization in health research: using appropriate genetic variants and avoiding biased 
estimates. Econ Hum Biol. 2014;13:99-106. 
10. Galesloot TE, Janss LL, Burgess S, Kiemeney LALM, den Heijer M, de Graaf J, 
 
 
23 
 
Holewijn S, Benyamin B, Whitfield JB, Swinkels DW, Vermeulen SH. Iron and hepcidin as 
risk factors in atherosclerosis: what do the genes say? BMC Genetics. 2015;16:79. 
11. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of 
Mammalian iron metabolism. Cell. 2010;142:24-38. 
12. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey 
Smith G, Sterne JA. Using multiple genetic variants as instrumental variables for modifiable 
risk factors. Stat Methods Med Res. 2012;21:223-242. 
13. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G, Sterne JA. 
Mendelian randomization: using genes as instruments for making causal inferences in 
epidemiology. Stat Med. 2008;27:1133-1163. 
14. Thompson JR, Minelli C, Del Greco M F. Mendelian Randomization using Public 
Data from Genetic Consortia. Int J Biostat. 2016;12. 
15. Paaby AB, Rockman MV. The many faces of pleiotropy. Trends Genet. 2013;29:66- 
73. 
16. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal 
inference in observational epidemiology. PLoS medicine. 2008;5:e177. 
17. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, Paul DS, Freitag 
D, Burgess S, Danesh J, Young R, Butterworth AS. PhenoScanner: a database of human 
genotype-phenotype associations. Bioinformatics. 2016;32:3207-3209. 
  
 
 
24 
 
 
